Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib +/- Docetaxel in HER2+ Advanced Gastric Cancer
NCT02378389Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Sep 2014
- Primary completion
- Aug 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of pyrotinib in gastric cancer (GC) (2 arms), sponsored by Hengrui. Primary endpoint: Maximum Tolerated Dose at 21 days. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02378389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378389.